Cargando…

Response to Comment on “An Integrated Pharmacokinetic-Pharmacodynamic-Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia”

Detalles Bibliográficos
Autores principales:	Piena, Marjanne A., Houwing, Natalie, Kraan, Carla W., Wang, Xiaofeng, Waters, Heidi, Bennison, Craig
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9674709/ https://www.ncbi.nlm.nih.gov/pubmed/36357767 http://dx.doi.org/10.1007/s40273-022-01213-y

Ejemplares similares

An Integrated Pharmacokinetic–Pharmacodynamic–Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia
por: Piena, Marjanne A., et al.
Publicado: (2021)

Comment on “An Integrated Pharmacokinetic–Pharmacodynamic–Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia”
por: Rege, Bhaskar, et al.
Publicado: (2022)

Development of pharmacoeconomics guidelines for India
por: Thomas, Dixon, et al.
Publicado: (2014)

Pharmacoeconomic evaluations in the treatment of actinic keratoses
por: Tolley, Keith, et al.
Publicado: (2017)

Authors’ Reply to Ganijee et al.: “Comment on: Evaluation of the Influence of Sildenafil on Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vericiguat in Healthy Adults”
por: Boettcher, Michael, et al.
Publicado: (2023)

Response to Comments on “Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study”
por: Akizawa, Tadao, et al.
Publicado: (2019)

Comment on “Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU-Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?”
por: Webster, Christopher J., et al.
Publicado: (2019)

Pharmacoeconomical Concept in the Book of Rhazes, 10(th) Century AD
por: Hosseinkhani, Ayda, et al.
Publicado: (2019)

Systematic review of pharmacoeconomic models for schizophrenia
por: Zhou, Junwen, et al.
Publicado: (2018)

Comment on ‘Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety’
por: Koren, Andrew, et al.
Publicado: (2021)

Comment on: “Clinical Pharmacokinetics of Atypical Antipsychotics: An Update”
por: Periclou, Antonia, et al.
Publicado: (2019)

Pharmacodynamics and Pharmacokinetics of oral factor Xa inhibitors
por: Persson, Pontus B
Publicado: (2015)

Zolpidem pharmacokinetics and pharmacodynamics in metabolic interactions involving CYP3A: sex as a differentiating factor
por: Cubała, Wiesław Jerzy, et al.
Publicado: (2010)

Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies
por: Ravandi, F, et al.
Publicado: (2015)

Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece
por: Einarson, Thomas R, et al.
Publicado: (2012)

Comment on: Population pharmacokinetics and dosing optimization of mezlocillin in neonates and young infants
por: Standing, Joseph F
Publicado: (2022)

Pharmacodynamic Parameters of Pharmacokinetic/Pharmacodynamic (PK/PD) Integration Models
por: Zhang, Longfei, et al.
Publicado: (2022)

Comment on: "Preterm Physiologically Based Pharmacokinetic Model, Part I and Part II”
por: Völler, Swantje, et al.
Publicado: (2021)

Comment on: Neurocognitive Functioning in Schizophrenia, Their Unaffected Siblings and Healthy Controls: A Comparison
por: Rohilla, Jitendra
Publicado: (2016)

Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib
por: Liao, Mingxiang, et al.
Publicado: (2022)

Essentials of pharmacoeconomics
por: Rascati, Karen L.
Publicado: (2014)

Principles of pharmacoeconomics /
Publicado: (1996)

Pharmacoeconomic Aspects of Treating Hemorrhoidal Disease-Cost of Illness Study Based on Data from Balkan Country with Recent History of Social and Economic Transition
por: Božović, Bojana, et al.
Publicado: (2021)

Comment on “Increased in-hospital mortality from COVID-19 in patients with schizophrenia”. Considering the prevalence and protective factors of COVID-19 in patients with schizophrenia
por: Ekinci, O., et al.
Publicado: (2022)

Nirmatrelvir and COVID-19: development, pharmacokinetics, clinical efficacy, resistance, relapse, and pharmacoeconomics
por: Focosi, Daniele, et al.
Publicado: (2023)

Favorable pharmacokinetic and pharmacodynamic properties of gilteritinib in cerebrospinal fluid: a potential effective treatment in relapsing meningeal acute myeloid leukemia FLT3-ITD patients
por: Vignal, Nicolas, et al.
Publicado: (2023)

Comment on: “Enzalutamide: A Step Towards Pharmacokinetic-Based Dosing in Men with Metastatic Castration-Resistant Prostate Cancer”
por: Gibbons, Jacqueline A.
Publicado: (2015)

“Quantitative Pharmacology: An introduction to integrative pharmacokinetic-pharmacodynamic analysis”
por: Lowe, P J
Publicado: (2012)

Integrating Pharmacokinetics and Pharmacodynamics in Operational Research to End Tuberculosis
por: Alffenaar, Jan-Willem C, et al.
Publicado: (2020)

Pharmacokinetic and Pharmacodynamic Considerations for Drugs Binding to Alpha-1-Acid Glycoprotein
por: Smith, Sherri A., et al.
Publicado: (2018)

Pharmacokinetics and Pharmacodynamics of Posaconazole
por: Chen, Lu, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Ibrexafungerp
por: McCarthy, Matthew William
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Tedizolid
por: Iqbal, Khalid, et al.
Publicado: (2022)

Author’s Reply to: “Comment on: Pharmacokinetics and Safety of Recombinant Human Interleukin-1 Receptor Antagonist GR007 in Chinese Healthy Subjects”
por: Xie, Ran, et al.
Publicado: (2019)

Comment on “Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6”
por: Cattaneo, Dario, et al.
Publicado: (2021)

Cough up for just a cup of coffee: Pharmacoeconomics of depression
por: Swaminath, G.
Publicado: (2008)

Disease-relevant autoantibodies in first episode schizophrenia
por: Zandi, Michael S., et al.
Publicado: (2010)

Pharmacokinetic and Pharmacodynamic Integration and Modeling of Enrofloxacin in Swine for Escherichia coli
por: Wang, Jianyi, et al.
Publicado: (2016)

Integration of pharmacometabolomics with pharmacokinetics and pharmacodynamics: towards personalized drug therapy
por: Kantae, Vasudev, et al.
Publicado: (2016)

Urgency for Digital Technologies to Support Caregivers. Comment on “Telehealth-Based Psychoeducation for Caregivers: The Family Intervention in Recent-Onset Schizophrenia Treatment Study”
por: Eckardt, Jens Peter
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cm33liofvsivd3rg6eomrjl48d